Abstract
Editor—We thank Hu and colleagues1 for their interest in our study on the perioperative use of dexmedetomidine in patients undergoing cardiac surgery, in which we showed that dexmedetomidine infusion (initiated from cardiopulmonary bypass until tracheal extubation or 24 h) was associated with reduced death up to 5 yr after cardiac surgery.2 We initially found a higher 5-yr survival rate in patients who received dexmedetomidine compared with those who did not in the original unadjusted cohort of 2068 patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
